For research use only. Not for therapeutic Use.
Elexacaftor（Cat No.:I019109）, also known as VX-445, is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector. It is designed to address the underlying genetic defect in cystic fibrosis (CF) by improving CFTR protein function. Elexacaftor works by aiding in the folding and trafficking of CFTR to the cell surface, leading to increased chloride ion transport. This novel therapy has shown promising results in clinical trials, demonstrating improved lung function and reduced exacerbations in CF patients with specific genetic mutations. Elexacaftor represents a significant advancement in the treatment of CF.
| Catalog Number | I019109 |
| CAS Number | 2216712-66-0 |
| Molecular Formula | C₂₆H₃₄F₃N₇O₄S |
| Purity | 98% |
| Target | CFTR |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | CFTR |
| IUPAC Name | N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide |
| InChI | InChI=1S/C26H34F3N7O4S/c1-16-12-25(5,6)35(13-16)22-18(23(37)33-41(38,39)19-14-34(7)31-17(19)2)8-9-20(30-22)36-11-10-21(32-36)40-15-24(3,4)26(27,28)29/h8-11,14,16H,12-13,15H2,1-7H3,(H,33,37)/t16-/m0/s1 |
| InChIKey | MVRHVFSOIWFBTE-INIZCTEOSA-N |
| SMILES | C[C@H]1CC(N(C1)C2=C(C=CC(=N2)N3C=CC(=N3)OCC(C)(C)C(F)(F)F)C(=O)NS(=O)(=O)C4=CN(N=C4C)C)(C)C |
| Reference | [1]. Alexander Russell Abela, et al. MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR , PHARMACEUTICAL COMPOSITIONS , METHODS OF TREATMENT , AND PROCESS FOR MAKING THE MODULATOR. US 20180162839 A1.<br>[2]. Keating D, et al. VX-445-Tezacaftor-VX-770 in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620. |
